A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Inclusion Criteria: 1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL). 2. Have received ≥1 line of systemic antitumor therapy. 3. At least one bi-dimensionally measurable lesion. 4. Expected survival of at least 3 months. 5. Age ≥18 years old and under 80 years old. 6. The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up. Exclusion Criteria: 1. Central nervous system lymphoma involvement. 2. Primary mediastinal (thymus) large B-cell lymphoma. 3. Patients who have only one prior line therapy and are candidates for stem cell transplantation. 4. A history of immunodeficiency. 5. A history of severe cardiovascular disease. 6. A history of other malignancies within 5 years prior to administration of the first dose.